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Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults. Although CLL has classically been associated with sec-
ond primary solid malignancies, such as lung and skin 
cancer, association with hematologic malignancies is less 
common.1 Most cases of concurrent AML and CLL are 
treatment related.  Specifically, alkylating agents such 
as chlorambucil and purine analogs such as fludarabine 
have been implicated.2,3 Given the long natural course 
of CLL and the use of chemotherapy agents with estab-
lished leukemogenic potential, increased acute leukemia 
would be expected.4 Nevertheless, patients with CLL 
do not have an increased incidence of acute leukemia, 
with the incidence rate of therapy-related AML follow-
ing CLL treatment being <1%.5,6 Robertson et al re-
ported only 7 cases AML or myelodysplastic syndrome 
(MDS) in 1374 cases of CLL, with nearly three-fourths 
of the patients having received treatment with alkylat-
ing agents.4 Cases in the absence of prior treatment are 
exceedingly rare. Only a minority of reports represent 
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de novo AML following untreated CLL or concomitant 
AML and CLL. Given the scarcity of reported cases, 
insight into treatment of such cases is limited.
We present a patient with previously untreated 
CLL who developed AML four years after initial diag-
nosis. After undergoing chemotherapy and allogeneic 
stem cell transplantation, he was in complete remis-
sion of both malignancies. We will review the impor-
tant features of synchronous AML and CLL, discuss 
hypotheses behind the phenomenon, and examine the 
treatment modalities used in this case and previously 
published reports.
CasE 
A 55-year-old white male with a past medical history of 
diverticulosis and osteoarthritis presented with asymp-
tomatic lymphocytosis prior to total knee replacement 
in January 2007. Flow cytometry at that time revealed 
a kappa-restricted monoclonal B-cell population that 
was CD5+, CD10-, CD19+, CD20+, and CD23+. 
the development of hematologic malignancy in the presence of chronic lymphocytic leukemia (CLL) 
is rare. We present a case of acute myeloid leukemia (amL) with del(7q) occurring in a patient with a 
4-year history of untreated CLL. application of flow cytometry and immunohistochemistry allowed for 
characterization of two distinct coexisting malignant cell populations. after undergoing induction and 
consolidation chemotherapy, the patient achieved complete remission of amL with the persistence of 
CLL. allogeneic transplantation was pursued given his unfavorable cytogenetics. subsequent matched 
unrelated donor allogeneic stem cell transplantation resulted in full engraftment and complete remission, 
with no evidence of amL or CLL. Due to a scarcity of reported cases, insight into treatment and prognosis 
in cases of concurrent amL and CLL is limited. however, prognosis seems dependent on the chemosen-
sitivity of amL. CLL did not have a detrimental effect on treatment or transplant outcome in our case. this 
is the first reported case of concomitant de novo amL and CLL to undergo allogeneic transplantation. the 
patient remained in complete hematologic and cytogenetic remission of both malignancies over a year 
after transplantation.
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He was diagnosed with Rai low risk disease CLL and 
treatment was deferred. He was in good health until 
February 2011 when he presented with a dry cough and 
worsening dyspnea after a presumed upper respiratory 
tract infection. Physical examination revealed tender 
cervical lymphadenopathy. Initial laboratory studies 
revealed a hemoglobin of 9.8 g/dL, a platelet count of 
59×103/mL, and a white blood cell count of 188×109/L 
with 5% neutrophils, 59% lymphocytes, and 33% blasts. 
The peripheral smear revealed the presence of two dis-
crete cells: large blasts with granulocytic maturation 
and small mature lymphocytes (Figure 1). 
Flow cytometry confirmed the presence of two dis-
crete abnormal cell populations: 46.5% of cells were 
identified as CD45dim cells consistent with blasts, 
which expressed immature myeloid immunopheno-
type of CD13+, CD33+, CD11c+, and HLADR+. 
Additionally, a second abnormal population of mono-
clonal mature B cells, accounting for 26.6% of cells, 
expressed CD5+, CD10-, CD19+, CD20+, CD23+, 
and kappa light chain restriction. Cytogenetic analysis 
revealed deletion 7q- in 3.8% of cells.
Based on the morphological and immunological 
features, the patient was diagnosed with AML French-
American-British (FAB) group M2 in the setting of 
B-cell CLL. At the time of diagnosis, he underwent 
successful 7+3+3 induction chemotherapy with cyta-
rabine, doxorubicin, and etoposide. The post-induction 
hospital course was complicated by Legionella pneumo-
nia, successfully treated with azithromycin. Repeat bone 
marrow biopsy showed residual CLL but no evidence 
of AML. Given the presence of deletion 7q-, alloge-
neic transplantation was pursued. After two rounds of 
high-dose cytarabine (HiDAC) consolidation chemo-
therapy, bone marrow biopsy showed sustained remis-
sion of AML with the persistence of CLL. His ECOG 
performance status was 0 and his Karnofsky score was 
90%. His two siblings had chronic medical conditions 
that precluded them as donors. Thus a matched unre-
lated donor (MUD) was arranged through the National 
Marrow Donor Program (NMDP). He underwent al-
logeneic transplantation in July 2011. Post-transplant 
evaluation revealed full donor chimerism (100% CD3, 
100% CD33, and 100% CD56). Bone marrow aspirate 
and biopsy no longer demonstrated findings of CLL or 
AML. The post-transplant course was complicated by 
acute grade III cutaneous graft-versus-host disease, as 
well as World Health Organization (WHO) grade III 
mucositis. More than a year after transplantation, the 
patient remains in complete hematologic and cytoge-
netic remission of both malignancies. Full donor chi-
merism has persisted off all immunosuppression. 
DIsCussIon
Multiple theories behind the development of simulta-
neous AML and CLL have been proposed. Since CLL 
is associated with immunoglobulin deficiencies, the 
risk for secondary malignancies is thought be related 
to immunosuppression.7 In treatment-related cases, 
the development of AML is hypothesized to be the se-
quelae of immunosuppression combined with cytotox-
icity and DNA damage induced by prior chemotherapy 
treatments.8 In cases of de novo disease, leukemogenic 
factors and gene susceptibility may contribute to an 
increased risk for secondary malignancy.7 Some have 
proposed that a common stem cell defect involving a 
pluripotential stem cell line capable of developing along 
two different cell lines causes the two malignancies to 
develop together.9 However, others have demonstrated 
that the phenomenon results from separate karyotype 
abnormalities in the myeloid and lymphoid lines, trig-
gering two separate neoplastic events.1,8,10 Myeloid and 
lymphoid clones often have different chromosomal ab-
normalities and therefore the association between de 
novo AML and CLL is likely to be coincidental. 
Our patient’s treatment was aimed at eradicating 
AML. Induction chemotherapy resulted in complete 
remission of AML, while the CLL clone persisted. This 
supports the notion that these two malignancies rep-
resent two distinct clonal disorders. He subsequently 
underwent HiDAC consolidation chemotherapy in 
an attempt to sustain remission until allogeneic trans-
plantation. A search through the NMDP identified a 
10/10 high resolution matched donor with major ABO 
incompatibility. Our patient’s indication for allogeneic 
transplantation was the diagnosis of AML with un-
favorable cytogenetics of 7q- deletion.11 For patients 
Figure 1. bone marrow aspirate smear showing two distinct cell 
populations: mature lymphocytes and blasts (Wright giemsa, 
×20).
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with unfavorable cytogenetics in complete remission of 
AML, allotransplantation leads to improved long-term 
survival (35% to 42%) compared with nontransplanta-
tion therapy (less than 20%).12-14 According to the cur-
rent guidelines from the European Group for Blood 
and Marrow Transplantation, the indications for allo-
transplantion in CLL are cases that are nonresponsive 
or refractory to fludarabine or cases with p53 deletion/
mutation (deletion 17p-).15 Neither of these indica-
tions were met. A myeloablative conditioning regimen 
consisting of fludarabine, busulfan, and low-dose total 
body irradiation was used with transplantation. Repeat 
bone marrow biopsy and flow cytometry after donor 
engraftment no longer demonstrated evidence of AML 
or CLL. 
To our knowledge, 14 cases of concomitant AML 
and untreated CLL have been reported since 1990.1,5,7-
10,16-23 Table 1 summarizes the treatment courses in the 
11 cases that reported clinical outcomes. Limited by age 
Table 1. Treatment outcomes in previously published cases of concomitant aML and CLL. 
Author, Year Treatment of AML/CLL Complete response achieved? Clinical Outcome
Caballero et al, 199216
induction chemotherapy  
(daunorubicin, cytarabine)
Consolidation chemotherapy 
(cytarabine and daunorubicin) 
aML with induction
CLL with consolidation Cr at 4 months
Tamul et al, 199417 Vincristine and prednisone no death at 2 months due to unrelated causes
Lima et al, 19969 none (hospice) no death at 5 months due to progressive aML
gomez et al, 19977 6-mercaptoprurine and prednisone no
death at 4 months due to 
progressive aML
Mateu et al, 199718 
induction chemotherapy 
(idarubicin, etoposide, 
cytarabine)
Salvage chemotherapy 
(mitoxantrone, cytarabine, 
etoposide)
Consolidation chemotherapy 
(etoposide, cytarabine)
aML with salvage chemo
CLL with consolidation
death at 6 months due to aML 
relapse
Miller et al, 20018 none (septic) no death within days due to sepsis
Muta et al, 200222 none (hospice) no death at 2 months due to brain hemorrhage
gottardi et al, 20061 Hydroxyurea and transfusions no death at 9 months due to progressive aML
Lu et al, 200623
induction chemotherapy 
(daunorubicin and cytarabine)
Consolidation chemotherapy, 
(cytarabine)
aML with induction
CLL with consolidation Cr, time unspecified
Carruli et al, 20075 induction chemotherapy, (unspecified) no
death at 3 weeks due to 
progressive aML
Katz et al, 201010 none (hospice) no death days later due to progressive aML
and comorbidities, only four patients underwent induc-
tion chemotherapy, with three achieving complete re-
mission of both malignancies. Treatment-related AML 
traditionally carries a shorter median survival than 
de novo cases.24 Due to the scarcity of reported cases, 
outcomes of concomitant de novo AML and CLL are 
unknown. However, prognosis in such cases seems to 
be dependent on the response of AML to induction 
chemotherapy and as thus should direct treatment.5 In 
our case, the presence of CLL did not have a detrimen-
tal effect on treatment of AML. Our patient’s clinical 
outcome reflects the high chemosensitivity of AML to 
the induction regimen and his good performance status, 
allowing a transplant procedure. 
In contrast to previously published cases, another 
unique feature of this case was that CLL persisted 
through consolidation therapy. In previous reports, 
induction-resistant CLL was responsive to consolida-
tion therapy. Two patients achieved complete remission 
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of AML with standard induction chemotherapy; salvage 
chemotherapy was required for induction failure in the 
third case.15,16,23 Cytarabine consolidation resulted in 
complete remission of CLL in each of these cases. In our 
case, CLL was still present after two cycles of HiDAC 
consolidation chemotherapy and was only eradicated 
through transplantation. Although HiDAC does not 
have a conventional role in the treatment of CLL, these 
reports demonstrate success in inducing remission. This 
role should be further investigated.
In conclusion, with continued advancements in 
technology and the widespread use of flow cytometry, 
the identification of underlying indolent leukemias will 
rise. Cases of concurrent malignancies will be seen more 
often. Published reports indicate that prognosis is de-
pendent on the chemosensitivity of AML and as thus 
should dictate treatment. In our case, allogeneic trans-
plantation aimed at maintaining durable remission of 
AML also resulted in complete remission of CLL.
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